Clinical trial
A Multi-center, Randomized, Double-blind, Placebo Parallel Controlled Phase III Clinical Trial for the Efficacy and Safety of Fugliglitinate Benzoate Tablets in Patients With Type 2 Diabetes Who Cannot be Effectively Controlled by Metformin
NCT05801627 is registered in ClinicalTrials.gov with Shenzhen Salubris Pharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Double-blind, Placebo Parallel Controlled Phase III Clinical Trial for the Efficacy and Safety of Fugliglitinate Benzoate Tablets in Patients With Type 2 Diabetes Who Cannot be Effectively Controlled by Metformin
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 6, 2020
- Completion date
- May 24, 2022
- Enrollment
- 408 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.